[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, May 30, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on May 23, 2018 ]
[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, May 30, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on May 23, 2018 ]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o ☐ ☐ (Check One): x ☐ ☐ For Period Ended: March 31, 2018 ☐ ☐ ☐ ☐ ☐ For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herei]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o ☐ ☐ (Check One): x ☐ ☐ For Period Ended: March 31, 2018 ☐ ☐ ☐ ☐ ☐ For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herei]
[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, April 23, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on EX-99.1 2 e]
[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, April 23, 2018 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on EX-99.1 2 e]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 ☒ ☐ ☐ (Check One): ☐ ☐ ☐ For Period Ended: December 31, 2017 ☐ ☐ ☐ ☐ ☐ For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained he]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 ☒ ☐ ☐ (Check One): ☐ ☐ ☐ For Period Ended: December 31, 2017 ☐ ☐ ☐ ☐ ☐ For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained he]
[______________ FORM 8-K ______________ CURRENT REPORT Date of Report (Date of earliest event reported): January 29, 2018 ______________ BIOSTAR PHARMACEUTICALS, INC. ______________ Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identificatio]
[Our ref.: PS/SC/B397/AUD3/pp February 2, 2018 100F Street NE Washington DC Dear Sirs, We have read Item 4.0l (a) of Biostar Pharmaceuticals, Inc's Form 8-K, which discusses the resignation of Mazars CPA Limited as its independent registered public accounting firm, and we agree with the statements ma]
